📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
65 announcements match the current filters (relevance ≥ 5).
Anupam Rasayan First Globally to Commercialize ETFA via Flow Chemistry; $600M Market Potential
Anupam Rasayan has become the first company globally to commercialize Ethyl trifluoroacetate (ETFA) using a proprietary continuous flow chemistry platform. The product targets a significant global addressable market estimated at USD 500–600 million, serving the life sciences, pharmaceutical, and performance materials sectors. By utilizing flow chemistry instead of traditional batch processes, the company achieves better safety, scalability, and a lower environmental footprint. This launch strengthens the company's position in complex fluorination chemistry across domestic and international markets, including the USA and Japan.
Key Highlights
First company in the world to commercialize ETFA production using continuous flow chemistry technology.
Targets a global addressable market for ETFA estimated between USD 500 million and USD 600 million.
ETFA is a critical fluorinated building block used in high-value pharmaceutical and life science applications.
The flow chemistry platform offers superior operational efficiency and reproducibility compared to conventional batch processes.
Product launch covers both domestic and international markets, including major regions like the USA and Japan.
👀 What to Watch
Investors should view this as a significant technological milestone that could enhance margins and market share in the specialty chemicals space. Monitor the revenue contribution from ETFA in upcoming quarterly results to gauge the speed of commercial ramp-up.
Anupam Rasayan Files Open Offer for 26% Stake in Bliss GVS Pharma at ₹299 Per Share
Anupam Rasayan India Limited has filed a Draft Letter of Offer with SEBI for a mandatory open offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited. The offer price is set at ₹299.00 per share, representing 26.00% of the target company's expanded voting share capital. The total potential cash consideration for this stake is approximately ₹829 crore. The tendering period is tentatively scheduled to open on July 16, 2026, and close on July 29, 2026.
Key Highlights
Mandatory open offer to acquire up to 2,77,26,848 shares (26% stake) of Bliss GVS Pharma Limited.
Offer price fixed at ₹299.00 per equity share, to be paid in cash.
Draft Letter of Offer filed with SEBI on June 8, 2026, by Manager to the Offer, SBI Capital Markets Limited.
Tentative schedule sets the offer opening date as July 16, 2026, and closing date as July 29, 2026.
The acquisition is triggered by an underlying Share Purchase Agreement (SPA) for substantial acquisition of shares and control.
👀 What to Watch
Investors should monitor the final SEBI observations on the Draft Letter of Offer and assess the strategic synergies of this acquisition for Anupam Rasayan against the significant capital outlay.
Anupam Rasayan Promoter Declares No Encumbrance on 31.80% Stake for FY26
Kiran Pallavi Investments LLC, a key promoter of Anupam Rasayan India Limited, has submitted its annual declaration under SEBI Takeover Regulations for the financial year ended March 31, 2026. The promoter entity holds 3,62,06,896 equity shares, which constitutes 31.80% of the company's total equity capital. The filing confirms that no direct or indirect encumbrances or pledges were created on these shares during the reporting period. This disclosure provides assurance regarding the stability of the promoter's shareholding.
Key Highlights
Promoter Kiran Pallavi Investments LLC holds a significant 31.80% stake in the company.
Declaration confirms zero shares were pledged or encumbered during the financial year 2025-26.
The filing involves 3,62,06,896 equity shares held by the promoter entity.
Compliance submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
👀 What to Watch
Investors can take comfort in the fact that a major portion of the promoter holding remains unencumbered, indicating no immediate debt-related stress at the promoter level. Maintain a watch on overall promoter holding trends in upcoming quarterly reports.
CRISIL Places Anupam Rasayan on 'Rating Watch' Following Bliss GVS Pharma Acquisition Plan
CRISIL has placed Anupam Rasayan's 'CRISIL A+' long-term and 'CRISIL A1' short-term ratings on 'Rating Watch with Developing Implications'. This action follows the company's plan to acquire a 43.3-48.2% stake in Bliss GVS Pharma, which involves a debt component of Rs 300 crore. While FY26 revenue grew to Rs 2,365 crore from Rs 1,439 crore, operating margins compressed to 22.19% from 27.67%. The company has shown significant improvement in its working capital cycle, with inventory days reducing from 510 to 324 days.
Key Highlights
CRISIL A+ rating assigned to new Rs 160 crore NCDs and placed on Watch Developing.
Total bank loan facilities enhanced to Rs 1,620 crore from Rs 1,369.82 crore.
FY26 revenue increased to Rs 2,365 crore, though margins fell to 22.19% due to limited cost pass-through.
Inventory days improved to 324 days (vs 510 days) and receivables to 148 days (vs 190 days).
Acquisition of Bliss GVS Pharma stake to be funded via Rs 300 crore debt and balance through equity.
👀 What to Watch
Investors should monitor the final funding mix of the Bliss GVS acquisition and its impact on the company's leverage. While the improvement in working capital is positive, the compression in operating margins warrants caution regarding cost management.
CRISIL Places Anupam Rasayan on 'Rating Watch' Following Bliss GVS Pharma Acquisition Plan
CRISIL Ratings has placed Anupam Rasayan India Limited's (ARIL) 'A+' rating on 'Rating Watch with Developing Implications' following the company's announcement to acquire a 43.3-48.2% stake in Bliss GVS Pharma. The acquisition is expected to be funded by ₹300 crore in debt and additional equity from a global investment fund. While FY26 revenue grew significantly to ₹2,365.46 crore, operating margins saw a compression to 22.19% from 27.67% in the previous year. The company's financial risk profile remains healthy with a net worth of ₹3,334 crore and improving working capital cycles.
Key Highlights
CRISIL placed ARIL's long-term (A+) and short-term (A1) ratings on 'Rating Watch with Developing Implications' due to the Bliss GVS Pharma acquisition.
Revenue for FY26 increased to ₹2,365.46 crore from ₹1,438.72 crore in FY25, driven by agrochemical and pharma segments.
Inventory days improved significantly, dropping to 324 days in FY26 from 510 days in FY25.
Total bank loan facilities rated were enhanced to ₹1,620 crore from ₹1,369.82 crore.
Liquidity remains strong with expected cash accruals of ₹280-350 crore against debt obligations of ₹40 crore in FY27.
👀 What to Watch
Investors should closely monitor the final funding mix and regulatory approvals for the Bliss GVS Pharma acquisition, as it will determine the long-term impact on leverage. While the business growth and working capital improvements are positive, the 'Rating Watch' indicates near-term uncertainty regarding the capital allocation strategy.
Anupam Rasayan FY26 Revenue Jumps 65% to ₹2,384 Cr; Announces Bliss GVS Pharma Acquisition
Anupam Rasayan delivered a landmark FY26 with consolidated revenue growing 65% Y-o-Y to ₹2,384 crores and PAT increasing to ₹222 crores. The company successfully diversified its revenue mix, reducing agrochemical dependence from 76% to 55% while scaling Pharma and Performance Materials. A significant strategic acquisition of Bliss GVS Pharma (43.3% to 48.2% stake) was announced to create an integrated pharmaceutical platform. Management reported strong operating cash flows of ₹334 crores and the completion of its major capex cycle, signaling a shift toward higher asset utilization.
Key Highlights
FY26 consolidated revenue reached ₹2,384 crores, up 65% Y-o-Y, with an EBITDA margin of 23%.
Pharma segment revenue grew 15-fold from ₹21 crores in FY22 to ₹339 crores in FY26.
Announced acquisition of 43.3% to 48.2% stake in Bliss GVS Pharma to expand into formulations and CDMO.
Operating cash flow improved significantly to ₹334 crores due to better working capital management.
Jayhawk Fine Chemicals acquisition completed with pro forma annual revenue of approximately $76 million.
👀 What to Watch
Investors should view the aggressive diversification into Pharma and the completion of the capex cycle as long-term value drivers. Monitor the integration of Bliss GVS and Jayhawk for synergy benefits and margin expansion in FY27.
Anupam Rasayan Allots ₹160 Crore NCDs to Aditya Birla Capital at 10.25% Interest
Anupam Rasayan India Limited has successfully allotted 16,000 secured, unlisted Non-Convertible Debentures (NCDs) worth ₹160 crore to Aditya Birla Capital. The debt carries a coupon rate of 10.25% p.a. and has a short tenure of 13 months, maturing in June 2027. A significant partial redemption of ₹99,500 per NCD is scheduled for September 2026, effectively making it a very short-term bridge loan. The funds are intended for debt repayment, group investments, and general corporate purposes.
Key Highlights
Allotment of 16,000 NCDs with a face value of ₹1,00,000 each, totaling ₹160 crore.
Fixed coupon rate of 10.25% p.a. with interest and partial principal payable by September 2026.
Secured by a first-ranking pledge over 31,50,000 shares held by Promoter Mr. Anand Sureshbhai Desai.
Proceeds to be utilized for repayment of existing debt facilities and investment in group companies.
The instrument is unlisted and was issued on a private placement basis to Aditya Birla Capital Limited.
👀 What to Watch
Investors should monitor the company's interest coverage ratio given the 10.25% cost of debt and the increase in promoter share pledging. The structured early redemption suggests this is a temporary liquidity arrangement rather than long-term leverage.
Anupam Rasayan FY26 Revenue Jumps 65% to ₹23,836 Mn; Annual PAT Up 39%
Anupam Rasayan reported a landmark FY26 with consolidated revenue growing 65% YoY to ₹23,836 Mn, driven by the Jayhawk acquisition and new product launches. While annual PAT rose 39% to ₹2,222 Mn, Q4 performance saw a slight dip in margins with PAT falling 11% YoY to ₹560 Mn. The company achieved its highest-ever operating cash flow of ₹3,343 Mn and is expanding its pharma presence through a stake acquisition in Bliss GVS Pharma. The integration of Jayhawk and focus on high-value chemistries like Performance Materials remain key growth drivers.
Key Highlights
Consolidated FY26 revenue increased by 65% YoY to ₹23,836 Mn, while EBITDA grew 32% to ₹5,430 Mn.
Annual Profit After Tax (PAT) reached ₹2,222 Mn, representing a 39% growth compared to the previous financial year.
Successfully completed the acquisition of US-based Jayhawk Fine Chemicals and signed an agreement for Bliss GVS Pharma.
Achieved highest-ever operating cash flow of ₹3,343 Mn, reflecting improved operational efficiency and business scale.
Revenue mix diversified with Agrochemicals at 55%, Pharma at 20%, and Performance Materials at 18%.
👀 What to Watch
Investors should focus on the successful integration of Jayhawk and the upcoming Bliss GVS acquisition as they pivot the company toward higher-margin segments. While Q4 margins were slightly pressured, the strong annual cash flow and robust product pipeline support a long-term growth thesis in the CDMO space.
Anupam Rasayan FY26 Revenue Surges 65% to ₹23,836 Mn; Strategic Acquisitions Drive Growth
Anupam Rasayan reported a strong FY26 with consolidated revenue growing 65% YoY to ₹23,836 Mn and PAT increasing 39% to ₹2,222 Mn. The year was marked by the successful integration of Jayhawk Fine Chemicals and a new agreement to acquire a controlling stake in Bliss GVS Pharma. While annual performance was robust, Q4FY26 saw a margin contraction with EBITDA declining 6% YoY despite revenue growth. The company achieved its highest-ever operating cash flow of ₹3,343 Mn, supported by new product launches and expanded MNC partnerships.
Key Highlights
Consolidated FY26 revenue reached ₹23,836 Mn, a 65% YoY increase, driven by new products and acquisitions.
Full-year PAT grew 39% YoY to ₹2,222 Mn, though Q4 PAT declined 11% to ₹560 Mn due to margin pressure.
Completed the acquisition of US-based Jayhawk Fine Chemicals and signed a deal for Bliss GVS Pharma.
Generated record operating cash flow of ₹3,343 Mn, reflecting improved operational efficiency.
Diversified revenue mix with Agrochemicals at 55% and Performance Materials growing to 18%.
👀 What to Watch
Investors should monitor the successful integration of recent acquisitions and the recovery of margins which dipped in Q4. The shift towards high-value performance materials and pharma provides a long-term growth runway.
Anupam Rasayan to Acquire 43.3-48.2% Stake in Bliss GVS Pharma; Open Offer Announced
Anupam Rasayan India Limited has entered into a definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma Limited, alongside an open offer to public shareholders. The acquisition is being financed through a Rs 300 crore term loan and non-controlling non-voting equity instruments. This strategic move aims to create an integrated life sciences platform, combining Anupam's specialty chemical expertise with Bliss GVS's finished dosage formulation capabilities. Bliss GVS brings a portfolio of over 150 branded formulations and US FDA/EU-GMP approved manufacturing facilities.
Key Highlights
Acquisition of 43.3-48.2% equity stake in Bliss GVS Pharma plus a mandatory Open Offer
Financing structured via Rs 300 crore term loan and non-voting equity instruments
Bliss GVS is a global leader in suppositories and pessaries with 150+ branded formulations
Strategic vertical integration from Key Starting Materials (KSMs) to finished dosage forms
Access to US FDA, WHO-GMP, and EU-GMP certified manufacturing facilities in Maharashtra and Daman
👀 What to Watch
This is a major strategic expansion for Anupam Rasayan into the pharmaceutical formulation space; investors should monitor the acquisition valuation and the progress of the open offer. The integration is expected to unlock synergies in regulated markets like Europe and the US.
Anupam Rasayan to Acquire 43.3%-48.2% Stake in Bliss GVS Pharma
Anupam Rasayan (ANURAS) has entered into a definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma, along with a mandatory Open Offer to public shareholders. The acquisition is being financed through a Rs 300 crore term loan and non-controlling non-voting equity instruments for the balance. This strategic move allows ANURAS to vertically integrate its business from custom synthesis (KSMs) to finished dosage formulations. Bliss GVS brings a diversified portfolio of over 150 branded formulations and a strong international presence across Africa, Asia, and Latin America.
Key Highlights
Acquisition of 43.3% to 48.2% equity stake in Bliss GVS Pharma plus an Open Offer.
Financing includes a Rs 300 crore term loan and non-controlling non-voting equity instruments.
Bliss GVS Pharma offers a portfolio of 150+ branded formulations with US FDA and EU-GMP certified facilities.
Strategic shift towards an integrated life sciences platform spanning KSMs to finished dosages.
👀 What to Watch
Investors should view this as a major strategic expansion that enhances the company's value chain and market reach. Monitor the final acquisition price and the impact of the Rs 300 crore debt on the company's leverage ratios.
Anupam Rasayan to Acquire 74.2% Stake in Bliss GVS Pharma; Recommends ₹1.5 Dividend
Anupam Rasayan has announced a major strategic move to acquire up to 74.20% stake and control of Bliss GVS Pharma Limited, a listed entity. To support its capital requirements, the board has also approved a fundraise of ₹160 crore through the issuance of secured Non-Convertible Debentures (NCDs). Additionally, the company recommended a final dividend of ₹1.5 per share for FY26. While the Deputy CFO has resigned, the company reported audited financial results with an unmodified auditor opinion.
Key Highlights
Proposed acquisition of up to 74.20% equity stake and control of Bliss GVS Pharma Limited.
Recommended a final dividend of ₹1.5 per equity share (15% of face value) for FY 2025-26.
Approved raising ₹160 crore through private placement of 16,000 secured, rated, unlisted NCDs.
Resignation of Mr. Vishal Thakkar from the position of Deputy CFO and Key Managerial Personnel.
Audited financial results for FY26 approved with an unmodified audit opinion from statutory auditors.
👀 What to Watch
Investors should closely monitor the valuation and synergy potential of the Bliss GVS Pharma acquisition, as it is a significant expansion. The fundraise via NCDs indicates capital intensity, so checking the impact on the company's leverage is advised.
Anupam Rasayan to Acquire 43.3-48.2% Stake in Bliss GVS Pharma Plus Open Offer
Anupam Rasayan has entered into a definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma, followed by an Open Offer to public shareholders. The acquisition is financed through a ₹300 crore term loan and non-controlling non-voting equity instruments for the balance. This strategic move allows Anupam Rasayan to integrate its pharmaceutical value chain from Key Starting Materials (KSMs) to finished dosage formulations. Bliss GVS brings a portfolio of over 150 branded formulations and niche leadership in the suppositories and pessaries segment with US FDA and EU-GMP certified facilities.
Key Highlights
Acquisition of 43.3% to 48.2% stake in Bliss GVS Pharma plus a mandatory Open Offer.
Deal financing includes a ₹300 crore term loan and non-voting equity instruments.
Bliss GVS Pharma has a diversified portfolio of 150+ branded formulations across therapeutic areas like anti-malarial and women's healthcare.
Strategic integration from specialty chemicals/KSMs to finished dosage forms to unlock global synergies.
Access to Bliss GVS's manufacturing facilities with US FDA, WHO-GMP, and EU-GMP approvals.
👀 What to Watch
Investors should view this as a significant vertical integration move that expands Anupam Rasayan's addressable market into formulations. Monitor the Open Offer pricing and the impact of the ₹300 crore debt on the company's balance sheet in the upcoming quarters.
Anupam Rasayan Deputy CFO Vishal Thakkar Resigns with Immediate Effect
Anupam Rasayan India Limited has announced the resignation of Mr. Vishal Thakkar from his role as Deputy Chief Financial Officer and Key Managerial Personnel, effective May 23, 2026. Mr. Thakkar, who served the company for four years, was notably involved in the firm's M&A activities during his tenure. He is stepping down to explore other opportunities within the group and to focus on his own company. The resignation was processed during a board meeting that concluded at 4:55 p.m. IST on the same day.
Key Highlights
Resignation of Mr. Vishal Thakkar as Deputy CFO and KMP effective May 23, 2026
Mr. Thakkar completes a 4-year tenure with the company
Reason for exit includes exploring other group opportunities and personal business ventures
Board meeting regarding the resignation lasted approximately 4 hours and 10 minutes
👀 What to Watch
Investors should monitor the company's next steps regarding the appointment of a successor to ensure continuity in financial leadership. The transition appears amicable as the executive remains within the group ecosystem.
Anupam Rasayan to Acquire up to 74.2% Stake in Bliss GVS Pharma for ₹2,198 Crore
Anupam Rasayan (ANURAS) has approved the acquisition of a controlling stake of up to 74.20% in Bliss GVS Pharma at a price of ₹299 per share. The deal structure includes an initial 43.30% stake purchase for ₹1,369.51 crore, a mandatory open offer for 26% at ₹829.03 crore, and a call option for an additional 4.90%. Bliss GVS Pharma, which reported a turnover of ₹1,000.64 crore in FY26, provides ANURAS with strategic forward integration into finished dosage formulations and a global footprint in over 60 countries. This acquisition aims to create a diversified pharmaceutical platform by combining advanced chemistry with niche manufacturing capabilities.
Key Highlights
Acquisition of up to 74.20% stake in Bliss GVS Pharma at a fixed price of ₹299 per share.
Total cash consideration for the 43.30% SPA stake and 26% open offer totals approximately ₹2,198.54 crore.
Target company Bliss GVS Pharma reported FY26 consolidated turnover of ₹1,000.64 crore and a net worth of ₹1,231.76 crore.
Strategic forward integration from Key Starting Materials (KSMs) to finished dosage formulations (suppositories, tablets, capsules).
The transaction is expected to be completed within 6 months, subject to customary conditions and SEBI regulations.
👀 What to Watch
Investors should view this as a major growth move that transforms ANURAS into an integrated pharmaceutical player, though the funding of this ₹2,198 crore acquisition should be monitored for its impact on the balance sheet. Existing shareholders of Bliss GVS Pharma should evaluate the open offer price of ₹299 against current market valuations.
Anupam Rasayan to Acquire Up to 74.2% Stake in Bliss GVS Pharma for ~₹2,200 Cr
Anupam Rasayan has approved the acquisition of a controlling stake of up to 74.20% in Bliss GVS Pharma at a price of ₹299 per share. The deal involves an initial 43.30% stake purchase via a Share Purchase Agreement for ₹1,369.51 crore and a mandatory open offer for an additional 26% stake valued at ₹829.03 crore. This acquisition is a strategic forward integration move, allowing Anupam Rasayan to expand from specialty chemicals and KSMs into finished pharmaceutical dosages. Bliss GVS Pharma, which has a presence in over 60 countries, reported a consolidated turnover of ₹1,000.64 crore for FY26.
Key Highlights
Acquisition of up to 74.20% stake in Bliss GVS Pharma at a fixed price of ₹299 per share.
Initial 43.30% stake purchase via SPA for ₹1,369.51 crore and 26% open offer for ₹829.03 crore.
Target company Bliss GVS Pharma reported FY26 consolidated turnover of ₹1,000.64 crore and net worth of ₹1,231.76 crore.
Strategic forward integration from Key Starting Materials (KSMs) to finished dosage formulations.
Includes a call option to acquire an additional 4.90% residual stake from sellers within 12 months.
👀 What to Watch
This is a transformative acquisition that significantly expands Anupam Rasayan's value chain and global footprint. Investors should monitor the successful completion of the open offer and the subsequent margin improvements from forward integration.
Anupam Rasayan to Acquire 74.2% Stake in Bliss GVS Pharma; Declares INR 1.5 Dividend
Anupam Rasayan has announced a major strategic move to acquire up to 74.20% stake and control of Bliss GVS Pharma Limited, a listed entity. Alongside this, the company declared a final dividend of INR 1.5 per share for FY26 and approved a fundraise of INR 160 crore through private placement of NCDs. The board also accepted the resignation of Deputy CFO Vishal Thakkar while approving the audited financial results for the year ended March 31, 2026.
Key Highlights
Acquisition of up to 74.20% equity stake and control of Bliss GVS Pharma Limited.
Recommended final dividend of INR 1.5 per equity share (15% of face value) for FY 2025-26.
Approved fundraise of INR 160 crore via 16,000 Secured, Rated, Unlisted, Redeemable NCDs.
Audited standalone and consolidated financial results for FY26 approved with unmodified audit opinion.
Resignation of Mr. Vishal Thakkar from the post of Deputy CFO and Key Managerial Personnel.
👀 What to Watch
Investors should closely track the acquisition details and the potential synergies between Anupam Rasayan and Bliss GVS Pharma. The aggressive expansion and fundraise suggest a growth-oriented phase, though the impact on the balance sheet should be monitored.
Anupam Rasayan Shareholders Approve Security Creation for Subsidiary Credit Facility
Anupam Rasayan shareholders have approved resolutions to provide guarantees and create security interests over the assets of material subsidiaries, Doriath S.a.r.l. and Jayhawk Fine Chemicals Corporation. These measures secure a credit facility for Doriath S.a.r.l. from Altis XII Pte. Ltd. Both resolutions received overwhelming support, with approximately 99.94% of votes cast in favor. This approval facilitates the company's ability to maintain and manage debt for its international operations.
Key Highlights
Approved guarantees for credit facility availed by Doriath S.a.r.l. from Altis XII Pte. Ltd.
Authorized security creation over assets of material subsidiaries Doriath S.a.r.l. and Jayhawk Fine Chemicals.
Resolution 1 passed with 99.94% majority (83,892,813 votes in favor).
Resolution 2 passed with 99.94% majority (83,892,713 votes in favor).
The approval covers the facility even if Doriath S.a.r.l. ceases to be a wholly-owned subsidiary.
👀 What to Watch
Monitor the impact of this credit facility on the company's consolidated balance sheet and interest coverage ratio. The strong shareholder support reflects confidence in the company's expansion and financing strategy.
Anupam Rasayan Shareholders Approve Subsidiary Financing Guarantees with 99.9% Majority
Anupam Rasayan India Limited has announced the successful passage of two key resolutions through a postal ballot with over 99.9% shareholder approval. The first resolution allows the company to provide guarantees for credit facilities of its subsidiary, Doriath S.a.r.l., even if its ownership status changes in the future. The second resolution authorizes the creation of security interests over the assets of Doriath S.a.r.l. and Jayhawk Fine Chemicals Corporation. These approvals provide the company with significant financial flexibility and ensure continued support for its international operations.
Key Highlights
Shareholders approved guarantees for Doriath S.a.r.l. with a 99.94% majority, representing 83.89 million votes in favor.
Special resolution for security interests over Jayhawk Fine Chemicals assets passed with 99.94% support.
Total voter turnout was approximately 73.74% of the total outstanding shares, with 100% promoter participation in favor.
The resolutions facilitate credit facilities for international subsidiaries, ensuring operational liquidity and strategic flexibility.
👀 What to Watch
Investors should monitor for any potential divestment or strategic partnership involving Doriath S.a.r.l., as these resolutions provide the necessary financial framework for such transitions.
CRISIL Reaffirms Anupam Rasayan’s 'A+' Rating; Removes Negative Watch on ₹1369.82 Cr Debt
CRISIL has reaffirmed Anupam Rasayan's long-term rating at 'CRISIL A+/Stable' and removed it from 'Rating Watch with Negative Implications'. This resolution follows the successful integration of Tanfac Industries and a demonstrated improvement in the working capital cycle, with inventory days dropping from 270 to 210. The company maintained steady revenue of ₹1,101 crore in 9M FY24 with strong EBITDA margins of 27-28%. The stable outlook reflects the company's established market position and long-term contracts with global agrochemical and fluorochemical players.
Key Highlights
CRISIL reaffirmed Long-Term rating at 'A+/Stable' and Short-Term at 'A1' for ₹1369.82 crore bank facilities.
Removed 'Rating Watch with Negative Implications' following the successful acquisition and integration of Tanfac Industries.
Inventory days significantly improved to 210 days from 270 days, easing working capital pressure.
Reported 9M FY24 revenue of ₹1,101 crore with healthy operating margins sustained at 27-28%.
Net debt to EBITDA ratio is expected to remain manageable between 2.5x to 3.0x in the medium term.
👀 What to Watch
The removal of the negative watch indicates reduced financial risk and successful deleveraging post-acquisition. Investors should view this as a sign of operational stability, though they should continue to monitor the working capital cycle and global demand for specialty chemicals.
